Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)2022-07-072022-07-072019-05-02O'Bryant, S. E., Edwards, M., Zhang, F., Johnson, L. A., Hall, J., Kuras, Y., & Scherzer, C. R. (2019). Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. Alzheimer's & dementia (Amsterdam, Netherlands),11, 374-382. https://doi.org/10.1016/j.dadm.2019.03.0012352-8729https://hdl.handle.net/20.500.12503/31536Introduction: We sought to determine if our previously validated proteomic profile for detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD from other neurodegenerative diseases. Methods: Plasma samples were assayed from 150 patients of the Harvard Biomarkers Study (PD, n = 50; other neurodegenerative diseases, n = 50; healthy controls, n = 50) using electrochemiluminescence and Simoa platforms. Results: The first step proteomic profile distinguished neurodegenerative diseases from controls with a diagnostic accuracy of 0.94. The second step profile distinguished PD cases from other neurodegenerative diseases with a diagnostic accuracy of 0.98. The proteomic profile differed in step 1 versus step 2, suggesting that a multistep proteomic profile algorithm to detecting and distinguishing between neurodegenerative diseases may be optimal. Discussion: These data provide evidence of the potential use of a multitiered blood-based proteomic screening method for detecting individuals with neurodegenerative disease and then distinguishing PD from other neurodegenerative diseases.http://creativecommons.org/licenses/by-nc-nd/4.0/blood biomarkersdiagnostic accuracyParkinson's diseaseParkinson DiseasePrecision MedicineProteomicsArticleCopyright © 2019 The Authors11